US-based cancer analysis technology developer Xilis completed a $70m series A round yesterday featuring GV, a corporate venture capital subsidiary of internet and technology group Alphabet.
The Abu Dhabi state-owned Mubadala Capital led the round, which included LSP, Catalio Capital Management, Duke Endowment and Duke Angel Network, Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures and Alix Ventures.
Founded in 2019, Xilis is working on a precision oncology platform designed to help enhance cancer care and drug discovery and development. The capital will be used to further develop its MicroOrganoSphere technology and support clinical studies.
Xilis founder and chief executive Xiling Shen said: “Our vision is to transform cancer care in diagnostics and reshape drug development by providing a technology for rapid therapeutic profiling.
“The support provided by these world-class investors is an important milestone for our journey to transform cancer care and dramatically improve patient survival by enabling personalised precision oncology and bringing transformative medicines to patients faster and with higher success rates.”
Felicis Ventures had previously joined fellow venture capital firms Liquid 2 Ventures, Pear and 8VC to provide $3m in seed funding for the startup in November 2019, two months after a Pear-led pre-seed round.
